Nellson, Ganeden team to create probiotic nutrition bars
LOS ANGELES Nellson Nutraceutical and Ganeden Biotech on Thursday entered into a collaboration in the development of probiotic-enhanced nutrition bars and powdered products.
The collaboration agreement underscores the companies’ commitment to developing innovative probiotic fortified food and beverage products designed to improve quality of life and provide health and wellness benefits to consumers. Nellson’s technical expertise in the area of nutrition bars and powdered products coupled with Ganeden Biotech’s leadership in probiotic products and supplements will accelerate product development initiatives, the two companies stated.
Unlike many other popular probiotics strains, Ganeden Biotech’s patented probiotic strain, GanedenBC30, is easily able to survive harsh manufacturing conditions and is shelf-stable, making it an ideal probiotic for nutrition bars and powder products.
“Partnering with an industry leader such as Nellson will enable us to broaden the applications of GanedenBC30 into more functional foods, beverages and engineered nutraceuticals applications,” Andrew Lefkowitz, Ganeden Biotech president and chief executive officer said. “The experience, knowledge and high standard of quality that Nellson brings to the market further support our commitment to provide superior probiotic ingredients.”
“We look forward to a long-term collaborative relationship with Ganeden Biotech through which we can help advance functional food and beverage products and develop new applications for healthy functional ingredients, including probiotics,” Allan Lutz, president and chief executive officer of Nellson Nutraceutical said. “Ganeden Biotech’s leadership in probiotics, including food and beverage applications, will help us bring superior functional foods and beverages to consumers.”
Advertising council makes recommendations on Constellation Wines’ dietary claims
NEW YORK The National Advertising Division of the Council of Better Business Bureaus on Tuesday determined that Constellation Wines U.S./PolyPhenolics provided reasonable support for certain performance claims made for the company’s dietary supplement MegaNatural-BP, but recommended the company discontinue certain claims to avoid consumer confusion.
NAD was concerned that that the claim “Provide relief with half the cost, half the dose,” did not clearly identify the object of the comparison and suggested that consumers with high blood pressure could replace prescribed medication with a supplement.
NAD recommended that the advertiser discontinue the claim, “Provide relief with half the cost, half the dose and half the time” but noted that the advertiser can continue to discuss the differences between MegaNatural-BP and the competing Antigen Converting Enzyme (ACE) inhibitors which take 4-6 weeks of regular supplementation to work.
NAD recommended that to avoid the potential for any consumer confusion, and consistent with the findings of the studies on which it relies, the advertiser clearly and conspicuously disclose that MegaNatural-BP could be used as a part of a lifestyle management program for people with prehypertension and metabolic syndrome, and clearly state that consumers should “Consult your doctor before taking MegaNatural-BP.”
The company, in its advertiser’s statement, said it “understands NAD’s decision as written and appreciates your thorough and well-explained rationale. Polyphenolics agrees to modify its advertising as recommended.”
Congressman ask for review of Bayer aspirin heart health claims
WASHINGTON Two Michigan democrats have singled out Bayer’s marketing of its Aspirin with Heart Advantage, a combination product that includes a dietary supplement, that appears to go against a Food and Drug Administration’s request not to advertise such products, said House of Representatives Energy and Commerce Chairman John Dingell, according to a Reuters report published Tuesday.
Dingell, along with Rep. Bart Stupak, fired off two letters suggesting that the supplement/analgesic combination product might need FDA approval—one to Bayer and the other to Health and Human Services secretary Michael Leavitt. HHS oversees the FDA.